4,277 Johnson & Johnson $JNJ Shares Acquired by Sax Wealth Advisors LLC

Sax Wealth Advisors LLC boosted its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 11.7% during the 3rd quarter, Holdings Channel reports. The fund owned 40,886 shares of the company’s stock after buying an additional 4,277 shares during the period. Sax Wealth Advisors LLC’s holdings in Johnson & Johnson were worth $10,824,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of JNJ. Auto Owners Insurance Co lifted its position in Johnson & Johnson by 22,225.6% during the fourth quarter. Auto Owners Insurance Co now owns 69,419,308 shares of the company’s stock valued at $1,436,633,000 after acquiring an additional 69,108,368 shares during the last quarter. Jupiter Topco LLC acquired a new stake in Johnson & Johnson in the second quarter worth about $1,967,399,000. Diamant Asset Management Inc. raised its position in shares of Johnson & Johnson by 24,436.5% in the 1st quarter. Diamant Asset Management Inc. now owns 4,473,008 shares of the company’s stock valued at $109,338,000 after purchasing an additional 4,454,778 shares during the last quarter. Corient Private Wealth LP raised its holdings in shares of Johnson & Johnson by 127.3% in the second quarter. Corient Private Wealth LP now owns 6,060,922 shares of the company’s stock worth $1,539,292,000 after buying an additional 3,393,981 shares during the last quarter. Finally, Wellington Management Group LLP raised its holdings in shares of Johnson & Johnson by 12.5% in the second quarter. Wellington Management Group LLP now owns 22,588,696 shares of the company’s stock worth $5,736,851,000 after buying an additional 2,513,321 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Timothy Schmid sold 33,597 shares of the stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total value of $9,230,439.78. Following the sale, the executive vice president directly owned 25,447 shares of the company’s stock, valued at approximately $6,991,308.78. This represents a 56.90% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Jennifer L. Taubert sold 15,000 shares of the stock in a transaction on Monday, August 17th. The shares were sold at an average price of $263.36, for a total value of $3,950,400.00. Following the completion of the transaction, the executive vice president directly owned 194,451 shares in the company, valued at $51,210,615.36. This trade represents a 7.16% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 87,569 shares of company stock valued at $23,064,544 in the last three months. 0.16% of the stock is currently owned by insiders.

Johnson & Johnson Trading Down 6.7%

Shares of NYSE JNJ traded down $17.64 during midday trading on Tuesday, reaching $246.09. 6,065,245 shares of the stock were exchanged, compared to its average volume of 7,938,428. The stock has a market capitalization of $593.06 billion, a P/E ratio of 28.49, a PEG ratio of 2.65 and a beta of 0.21. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.81 and a current ratio of 1.09. The company has a 50 day simple moving average of $266.01 and a 200 day simple moving average of $249.31. Johnson & Johnson has a twelve month low of $184.66 and a twelve month high of $281.07.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, October 13th. The company reported $2.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.53 by $0.06. The firm had revenue of $25.40 billion for the quarter, compared to analyst estimates of $25.38 billion. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. Johnson & Johnson’s revenue was up 5.9% on a year-over-year basis. During the same period in the previous year, the firm earned $2.80 EPS. As a group, equities analysts expect that Johnson & Johnson will post 11.18 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 8th. Stockholders of record on Tuesday, August 25th were paid a $1.34 dividend. The ex-dividend date of this dividend was Tuesday, August 25th. This represents a $5.36 annualized dividend and a dividend yield of 2.2%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 62.11%.

Analysts Set New Price Targets

A number of equities research analysts recently commented on JNJ shares. Stifel Nicolaus set a $260.00 target price on Johnson & Johnson in a research report on Wednesday, July 15th. Wall Street Zen cut Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Saturday, August 1st. Royal Bank Of Canada boosted their target price on shares of Johnson & Johnson from $287.00 to $290.00 and gave the company an “outperform” rating in a research note on Tuesday, October 6th. Wells Fargo & Company lifted their price target on Johnson & Johnson from $272.00 to $282.00 and gave the company an “overweight” rating in a research note on Monday, August 3rd. Finally, Argus set a $300.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, July 29th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat, Johnson & Johnson has an average rating of “Moderate Buy” and an average target price of $276.22.

Johnson & Johnson News Roundup

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Quarterly results exceeded expectations: Adjusted earnings per share were $2.59 versus the $2.53 consensus, while revenue rose 5.9% year over year to $25.40 billion, slightly above estimates. Growth in Innovative Medicine helped support results. Johnson & Johnson Q3 Earnings Surpass Estimates
• Positive Sentiment: Full-year outlook was raised: J&J now expects 2026 adjusted EPS of approximately $11.05 to $11.15, signaling confidence in its operating momentum despite ongoing portfolio challenges. Johnson & Johnson reports Q3 2026 results
• Positive Sentiment: Dividend maintained: The board declared a quarterly dividend of $1.34 per share, payable December 8, reinforcing J&J’s appeal to income-focused investors. Johnson & Johnson Announces Quarterly Dividend
• Positive Sentiment: New long-term clinical data for TREMFYA showed sustained efficacy in Crohn’s disease, supporting the company’s pharmaceutical pipeline and efforts to offset Stelara-related pressure. TREMFYA Crohn’s disease data
• Neutral Sentiment: J&J is leaning toward spinning off its hips-and-knees business, a move that could sharpen the company’s focus but also creates execution and separation risks. J&J hips-and-knees spinoff
• Negative Sentiment: Reported profitability declined: Third-quarter EPS fell from $2.80 a year earlier, with special charges causing a sharp drop in reported profit despite higher sales. Johnson & Johnson Q3 profit report
• Negative Sentiment: MedTech remains a key concern: Surgery revenue declined, with Middle East conflict disrupting medical-device sales. The weakness raises questions about whether a potential spinoff can resolve the segment’s operational problems. Can a Spinoff Fix Johnson & Johnson’s MedTech Problem?

Johnson & Johnson Profile

Johnson & Johnson (NYSE: JNJ) is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.